Menu
Back to User profile » Dr Nancy A Risebrough
Papers published by Dr Nancy A Risebrough:
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
Halpin DM, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, Risebrough NA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2745-2755
Published Date: 25 October 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1633-1642
Published Date: 25 July 2022
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3105-3118
Published Date: 13 November 2021
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DMG, Han MK, Lomas DA
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2681-2695
Published Date: 29 November 2019
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study
Paly VF, Naya I, Gunsoy NB, Driessen MT, Risebrough N, Briggs A, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:939-951
Published Date: 3 May 2019
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective
Shah D, Risebrough NA, Perdrizet J, Iyer NN, Gamble C, Dang-Tan T
ClinicoEconomics and Outcomes Research 2018, 10:791-803
Published Date: 14 November 2018
Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources
Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, Risebrough NA, Slejko JF, Rutten-van Mölken MP
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3183-3194
Published Date: 1 November 2017